Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with BRAF V600E Mutation
Clinical Scenario
BRAF V600E+
This protocol applies to patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumour harbours a BRAF V600E mutation — a rare but actionable genomic alteration.
The BRAF V600E mutation occurs in 1% to 2% of patients with lung adenocarcinoma and is the most common of the BRAF mutations encountered in NSCLC. Identifying this mutation through molecular testing is essential, as it defines a distinct treatment pathway.
First-Line Treatment Approach
For this population, the recommended approach is first-line targeted therapy directed at the BRAF V600E alteration. Combination regimens are preferred; a single-agent option exists for patients who cannot tolerate the preferred combination.
The complete regimen options, sequencing guidance, and tolerability considerations are detailed in the full structured protocol.
References
- The BRAF V600E mutation occurs in 1% to 2% of patients with lung adenocarcinoma and is the most common of the BRAF mutations.
- The Panel recommends dabrafenib/trametinib or binimetinib/encorafenib as preferred first-line therapy options for patients with BRAF V600E mutation-positive advanced or metastatic NSCLC.
- Single-agent vemurafenib or dabrafenib are treatment options if the combination of dabrafenib/trametinib is not tolerated.
View source ↗